drugset / Trial / NCT00114920

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00114920

Phase 2 Completed 88 enrolled Graceway Pharmaceuticals, LLC
Non-randomizedSingle-groupSingle-blindTreatment

Summary

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.

Timeline

Start
2004-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule Topical

Indications